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Dr. Tans
Tel: (+3
Judith.vanPurpose: To evaluate the results of selective nodal irradiation on basis of 18F-deoxyglucose positron emission to-
mography (PET) scans in patients with limited-disease small-cell lung cancer (LD-SCLC) on isolated nodal failure.
Methods and Materials: A prospective study was performed of 60 patients with LD-SCLC. Radiotherapy was
given to a dose of 45 Gy in twice-daily fractions of 1.5 Gy, concurrent with carboplatin and etoposide chemother-
apy. Only the primary tumor and the mediastinal lymph nodes involved on the pretreatment PET scan were irra-
diated. A chest computed tomography (CT) scan was performed 3 months after radiotherapy completion and
every 6 months thereafter.
Results: A difference was seen in the involved nodal stations between the pretreatment 18F-deoxyglucose PET scans
and computed tomography scans in 30% of patients (95% confidence interval, 20–43%). Of the 60 patients, 39
(65%; 95% confidence interval [CI], 52–76%) developed a recurrence; 2 patients (3%, 95% CI, 1–11%) experi-
enced isolated regional failure. The median actuarial overall survival was 19 months (95% CI, 17–21). The median
actuarial progression-free survival was 14 months (95% CI, 12–16). 12% (95% CI, 6–22%) of patients experienced
acute Grade 3 (Common Terminology Criteria for Adverse Events, version 3.0) esophagitis.
Conclusion: PET-based selective nodal irradiation for LD-SCLC resulted in a low rate of isolated nodal failures
(3%), with a low percentage of acute esophagitis. These findings are in contrast to those from our prospective study
of CT-based selective nodal irradiation, which resulted in an unexpectedly high percentage of isolated nodal
failures (11%). Because of the low rate of isolated nodal failures and toxicity, we believe that our data support
the use of PET-based SNI for LD-SCLC.  2010 Elsevier Inc.
Selective nodal irradiation, small cell lung cancer, positron emission tomography, PET, combined modality treat-
ment, elective nodal irradiation.INTRODUCTION
The prognosis of patients with limited-disease small-cell lung
cancer (LD-SCLC) has improved significantly with the appli-
cation of accelerated radiotherapy (RT) and concurrent che-
motherapy (1), which have become the current standard
treatment. Although long-term survival rates of approxi-
mately 25% have been reached, more than 30% of patients
will still develop local failure with this treatment (1). Improv-
ing locoregional tumor control by simply increasing the radi-t requests to: Judith van Loon, M.D., Maastro Clinic,
laan 12, Maastricht NL-6229 ET The Netherlands.
1) 88-445-5666; Fax: (+31) 88-445-5667; E-mail:
loon@maastro.nl
329ation dose is not straightforward, because dose-limiting
toxicity occurs, consisting of severe reversible esophagitis
and lung damage (2–4). An attractive strategy to reduce the
toxicity is to diminish the radiation fields by omitting routine
elective nodal irradiation (ENI) of the mediastinum. This
strategy has proved its efficacy in non–small-cell lung cancer
(NSCLC), in which radiation fields could be safely reduced
by selective nodal irradiation (SNI), using computed tomog-
raphy (CT), and even further using 18F-deoxyglucose (FDG)Presented at the European Multidisciplinary Conference in Tho-
racic Oncology, Lugano, Switzerland, May 1–3, 2009.
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only FDG-positive mediastinal areas decreased the radiation
exposure to the lungs and the esophagus sufficiently to allow
for dose escalation in NSCLC (9, 10). Although selective
irradiation of clinically involved nodes is also regularly
applied in clinical practice for SCLC, no published data are
available supporting this practice. A recent report from the
International Atomic Energy Agency meeting emphasized
the need for prospective clinical evidence regarding SNI
for SCLC (11).
To date, only a few prospective data concerning SNI for
SCLC are available. In a previous Phase II trial from our
group, isolated nodal failures were observed outside of the
clinical target volume (CTV) in 11% of patients undergoing
SNI, using CT (12). These isolated nodal failures all occurred
in the ipsilateral supraclavicular fossa. Baas et al. (10) and
Belderbos et al. (13) reported an isolated nodal recurrence
in the ipsilateral supraclavicular fossa in 1 of 36 patients
treated with concurrent chemotherapy and CT-based in-
volved field irradiation. Although no definitive conclusions
could be drawn because of the small sample size, those find-
ings imply that the safety of SNI in NSCLC cannot be
straightforwardly extrapolated to SCLC patients. The avail-
able data suggest that FDG-PET scans are more accurate
than CT in the primary staging of SCLC (14–17). In a plan-
ning study on FDG-PET–based selective mediastinal node
irradiation in 21 LD-SCLC patients to investigate the poten-
tial role of FDG-PET in RT planning (18), we found a change
in the treatment plan compared with the CT-based plan in
24% of patients. Because of these results, we decided to pro-
spectively evaluate SNI based on FDG-PET for LD-SCLC.
Our primary endpoint was to evaluate the proportion of
isolated nodal failures; the secondary end points were the pat-
terns of recurrence and esophageal and pulmonary toxicity.METHODS AND MATERIALS
Patient population
Patients diagnosed with LD-SCLC and referred for radical RT to
Maastro Clinic between December 2004 and November 2006 were
prospectively evaluated. The inclusion criteria were cytologically or
histologically proven SCLC; limited disease, defined as Interna-
tional Union Against Cancer Stage I-III, with the exclusion of T4
lesions because of malignant pleural or pericardial effusion; World
Health Organization performance status 0–2; age $18 years; and
adequate pulmonary function (forced expiratory volume in 1 second
>1 L). Patients with severe recent cardiac disease (e.g., arrhythmia,
congestive heart failure, infarction) were excluded. The minimal
follow-up time after the start of RT was 18 months.Staging
All patients underwent bronchoscopy with biopsy and standard
hematologic and biochemical workup. Brain imaging was per-
formed with either magnetic resonance imaging or a contrast-
enhanced CT. Pretreatment imaging of the chest consisted of either
a whole body FDG-PET scan and a contrast-enhanced CT scan of
the chest or a combined whole body FDG-PET and CT scan with
contrast.Chest imaging with FDG-PET and CT
For PET-based RT planning, a combined PET-CT scan was per-
formed either during the diagnostic process only or during both the
diagnostic process and for RT simulation. In both cases, to ensure
optimal co-registration, the PET-CT scan was obtained with the
patient in the RT position with both arms above the head (19).
Patients had to have fasted for $6 h before the examination. The in-
jected total activity of FDG was calculated from the weight of the
patient: weight 4 + 20 MBq. After a rest period of 60 min (interval
needed for FDG uptake), the PET and CT images were acquired.
A CT scan of the whole thorax was performed with intravenous
contrast during free breathing.
Lymph nodes were judged positive and included in the CTV on
basis of the report of the PET and CT scans. The CT and PET find-
ings were interpreted and reported independently by an experienced
chest radiologist and nuclear medicine specialist, respectively.
The CT findings from the diagnostic CT scan were also inter-
preted by an experienced chest radiologist. Lymph nodes were con-
sidered to be pathologic on CT when their axial diameter was >1 cm.
The lymph nodes were considered positive on the FDG-PET scan on
basis of visual interpretation by an experienced PET scan specialist.
No quantitative standardized uptake value threshold was used,
because a visual scale has been shown to be at least as accurate as
the use of a standardized uptake value threshold to distinguish
benign from malignant nodes (20, 21). The involved lymph node
stations were recorded according to the Mountain and Dresler
classification scheme (22).Radiotherapy
For RT planning, contrast-enhanced CT or combined FDG-PET-
CT was performed that extended from the cricoid to the second lum-
bar vertebra, with a maximal slice thickness of 3 mm. Patients were
scanned in the supine position with both arms above the head. The
CT and PET images were automatically registered using a rigid reg-
istration technique based on mutual information and were subse-
quently fused using Focal software (Computerized Medical
System [CMS], St. Louis, MS). RT planning was performed with
a XiO treatment planning system (CMS), using inhomogeneity cor-
rections based on a convolution algorithm. For all patients, the gross
tumor volume (GTV) and planning target volume (PTV) were de-
fined on basis of the PET and CT data. In the case of induction che-
motherapy, the postchemotherapy volume was considered the GTV
of the primary tumor, whereas for the lymph nodes, only the pre-
treatment extension was considered. For the primary tumor, the
GTV was delineated using the CT findings only, using lung window
settings (W = 1,700, L =300). We deliberately avoided contouring
on the basis of ill-defined areas on the PET scan. Instead, the sharp
boundaries of the CT scan images were used. For planning of the
lymph nodes, the pretreatment anatomic sites of the involved zones
on the FDG-PET scan were delineated on the planning CT scan in
a mediastinal window setting (W = 600, L = 40). The whole patho-
logic anatomic region as described by the nuclear medicine special-
ist in the original diagnostic report (i.e., before the start of
chemotherapy) was delineated (23). If the PET scan was negative
in the mediastinum and the CT scan positive, the mediastinum
was not included in the GTV. The margin from the GTV to the
CTV was 5 mm, and from the CTV to the PTV was 5 mm for the
nodal areas and 10 mm for the primary lung tumor. No elective
nodal irradiation was performed.
Contouring of the lung was done automatically by the treatment
planning system. The mean lung dose (MLD) was analyzed as a pos-
sible predictor for radiation pneumonitis. For the calculation of the
Table 1. Toxicity grading criteria according to Common Terminology Criteria for Adverse Events, version 3.0
Adverse event
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(24). The dose constraint to the lungs was set at a MLD of 19 Gy.
The esophagus was delineated from just below the larynx to the gas-
troesophageal junction. Neither the GTV nor the PTV was sub-
tracted from this volume. The mean esophageal dose (MED) and
the maximal esophageal dose (Dmax) were analyzed as possible
predictors of early and late esophageal toxicity (24, 25). The spinal
cord was drawn throughout the whole CT scan and was considered
to be at the inner margin of the bony spinal canal. The maximal al-
lowed dose to the spinal cord was 54 Gy, and this dose constraint
was not reached in the present study.
All patients were treated with a three-dimensional conformal
treatment plan using 6–10-MV photons. The prescribed dose to
the PTV was 45 Gy in 30 fractions within 3 weeks (1.5 Gy twice
daily, with a minimal interval between two fractions of 8 h) accord-
ing to the International Commission on Radiation Units and Mea-
surements report 50 guidelines (26). During RT, patients were
seen weekly by the radiation oncologist for the evaluation of acute
side effects.
Chest RT was planned to start as early as possible after the be-
ginning of chemotherapy. After thoracic irradiation and 5 cycles
of chemotherapy, repeat staging was performed, including a chest
X-ray and contrast-enhanced CT scan or magnetic resonance im-
aging of the brain. If no progression was found on the chest X-ray
and no brain metastases were seen, the patients were offered pro-
phylactic cranial irradiation (PCI) to a dose of 25 Gy in 10 frac-
tions.Chemotherapy
Patients underwent chemotherapy according to the standard pro-
tocol in the Comprehensive Cancer Centre Limburg (The Nether-
lands). The standard protocol was carboplatin on Day 1 and
etoposide (120 mg/m2) on Days 1–3. The carboplatin dose was
based on the target area under the curve (5 mg/mL/h) (glomerular
filtration rate + 25), with the glomerular filtration rate calculated ac-
cording to the Cockroft-Gault formula. The chemotherapy cycles
were repeated every 21 days for a total of 5 cycles.Post-treatment follow-up
The follow-up consisted of a visit 3 weeks after the end of RT for
the evaluation of acute side effects. Thereafter, visits every 3
months, including history taking and physical examination, were
performed, for the first 2 years. After this period, 6-month visits
were performed until 5 years after treatment. CT of the thorax was
performed 3 months after RT completion and every 6 months there-
after. When a patient presented with a recurrence outside of the fol-
low-up visits, chest imaging was performed with chest X-ray and
CT. After the detection of a recurrence, the follow-up visits were
continued at 3-month intervals, with the type of imaging guided
by the site of progression and the presence of symptoms.
Local tumor control was evaluated according to the criteria of
Green et al. (27). An isolated nodal recurrence was defined as recur-
rence in the regional nodes outside the CTV, in the absence of
in-field failure or distant metastases.
The pulmonary and esophageal toxicity were scored according to
the Common Terminology Criteria for Adverse Events, version 3.0
(Table 1) (28). Toxicity was scored before the start of RT, at the
weekly visits during RT, and at the follow-up visits.Ethics
The trial was performed in accordance with the Dutch laws and
regulations. The study protocol was registered at the National Insti-
tutes of Health clinical trial database, under NCT00572923.Statistical analysis
On basis of the planning study we had previously performed (18),
we hypothesized that introducing PET into the RT planning would
change the treatment fields in 25% of the patients compared with
CT-based planning (29). From the results of PET-based SNI for
NSCLC, we expected the percentage of isolated nodal failures to
not exceed 5%. As the upper bound of the 95% confidence interval
(CI), we used the observed 11% of isolated nodal failures with
CT-based SNI (12). To detect this rate of failures, $50 patients
were needed for the present study (30).
Table 2. Baseline patient and treatment characteristics
Characteristic Value (+/SD)
Age (y)









Lung function (median FEV1; %) 70.0  20.2
Tumor location
Right upper lobe 17 (28.3)
Right middle lobe 5 (8.3)
Right lower lobe 4 (6.7)
Left upper lobe 1 (18.3)
Left lower lobe 6 (10.0)
Right hilus 7 (11.7)


















Abbreviations: WHO = World Health Organization; FEV1 =
forced expiratory volume in 1 s; CTx = chemotherapy; RT = radio-
therapy; OTT = overall treatment time; SER = interval between start
of CTx and end of RT.
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or as a proportion, with the 95% CIs. The estimates of overall sur-
vival (OS) and progression-free survival rates were calculated
with the Kaplan-Meier method, on an intent-to-treat basis, starting
from the first day of RT. Correlations between the dose–volume
parameters and toxicity were calculated using a two-sided Spear-
man’s test or a chi-square test in the case of nominal variables.RESULTS
Patient and treatment characteristics
A total of 60 patients with LD-SCLC, referred to our insti-
tution between December 2004 and November 2006, were
included. The baseline patient characteristics are summarized
in Table 2. Most patients were male (67%). All patients
received chemotherapy, which in 97% consisted of carbopla-
tin-etoposide. One patient received carboplatin-paclitaxel,
because she was diagnosed with ovarian cancer during the
diagnostic workup. A total of 59 patients (98%) received
a dose of 45 Gy. Five patients were treated with sequentialchemoradiotherapy instead of concurrent chemoradiother-
apy. The reasons for this protocol violation were either
a too high MLD owing to the size of the primary tumor or
a delay in patient referral. One patient was not considered
fit enough to undergo accelerated RT with concomitant che-
motherapy and was therefore treated with 5 cycles of induc-
tion chemotherapy, followed by RT to a dose of 54 Gy in 30
once-daily fractions.
The median interval between the first day of chemotherapy
and the start of chest RT for patients treated with concurrent
chemoradiotherapy was 18.0 11.1 days (range,13 to 49).
The overall treatment time of RT was 21  3.7 days (range,
17–41). The median interval between the start of chemother-
apy and the end of RT (SER) was 39 34.0 days (range, 20–
176). The median SER for patients treated with concurrent
chemoradiotherapy was 38  11.6 days (range, 7–71). Of
the 60 patients, 50 (83%; 95% CI, 72–91%) received prophy-
lactic cranial irradiation.
A difference in mediastinal staging according to CT and
PET was observed in 30% (95% CI, 20–43%) of the 60
patients (Fig. 1). In 15% (95% CI, 8–26%), more nodal sta-
tions were involved on PET than on CT, and in 13% of
patients (95% CI, 7–24%) fewer nodal stations were involved
on PET than on CT. In 1 patient, nodal stations were involved
on PET that were not involved on CT and vice versa. In 3
patients (5%; 95% CI, 2–14%), supraclavicular nodal sta-
tions were involved on PET, but the CT scan was negative
for these stations.
Patterns of failure
An overview of the frequency and site of relapses is listed
in Table 3.
The minimal follow-up of all surviving patients was 18
months. The median follow-up for all patients was 18.5 
10.3 months (range, 3-52). Of the 60 patients, 39 (65%,
95% CI, 52–76%) developed a recurrence.
Two patients (3%; 95% CI, 1–11%) experienced an iso-
lated nodal recurrence. Both recurrences were treated with
concurrent chemoradiotherapy. The first patient, whose pri-
mary tumor was located in the left lower lobe, developed
a nodal recurrence in station 4R at 15 months after treatment.
Different nodal stations had been involved before treatment
on PET (stations 5 and 10L) and CT (station 10L), but station
4R was not involved before treatment on PET or CT. The sec-
ond patient, with the primary tumor located in the lingula of
the left lung, developed nodal recurrence in station 2L and the
left supraclavicular region, also 15 months after treatment.
Those stations were not involved before treatment on the
basis of PET or CT (only station 6 involved).
In 87% (95% CI, 73–94%), distant metastases (either iso-
lated or combined with local or nodal recurrence) were
present at recurrence. Nine patients (15%, 95% CI, 8–26%)
were diagnosed with isolated brain metastases, of whom 6
had previously received prophylactic cranial irradiation. A
nodal recurrence outside the treatment field combined with
recurrence inside the treatment field occurred in 5 patients
(8%; 95% CI, 4–18%). In 1 of them, the nodal recurrence
Fig. 1. Difference in involved nodal stations between positron emission tomography (PET) and computed tomography
(CT). (a) Representative image of patient with positive nodal station 7 on PET, with negative findings on CT. (b) Repre-
sentative image of patient with positive nodal station 4L on CT, with negative findings on PET.
PET-based selective nodal irradiation for SCLC d J. VAN LOON et al. 333occurred in a nodal station that was positive on CT, but neg-
ative on PET, and hence had not been included in the treat-
ment field.Survival
The median actuarial OS time for all patients was 19
months (95% CI, 17–21; Fig. 2), with a 2-year OS rate of
35% (95% CI, 24–48%). The median OS for patients treated





In field 3 (5.0)
Out of field 4 (6.7)
Both in field and out of field 2 (3.3)
Isolated local 2 (3.3)
Local and distant/nodal 7 (11.7)
Nodal 20 (33.3)
In field 8 (13.3)
Out of field 7 (11.7)
Both in field and out of field 5 (8.0)
Isolated nodal 2 (3.3)
Nodal and distant/local 18 (30.0)
Distant 34 (56.7)
Isolated distant 19 (31.7)
Distant and local/nodal 15 (25.0)
Isolated brain 9 (15.0)
Abbreviation: CT = computed tomography.
Data in parentheses are percentages.CI, 16–22 months). The median actuarial PFS was 14 months
(95% CI, 12–16; Fig. 3), with a 2-year PFS rate of 17% (95%
CI, 9–28%).Toxicity
An overview of the dose volume histogram (DVH) param-
eters according to the toxicity grade is presented in Table 4.
The mean DVH parameters were as follows: mean MLD:
12.9  4.2 Gy; mean MED: 22.1  8.6 Gy; mean Dmax:
44.5  8.6 Gy. Treatment-related toxicity to the lungs was
relatively mild, with Grade 3 cough in 1 patient and Grade
3 dyspnea in 2 patients. However, 62% of patients experi-
enced acute esophagitis of Grade 2 or more, with 12%
(95% CI, 6–22%) experiencing Grade 3 esophagitis. The fre-
quency of Grade 3 esophagitis in patients treated withFig. 2. Actuarial overall survival.
Fig. 3. Actuarial progression-free survival.
Table 4. Dose–volume histogram parameters according to
toxicity grade*
Toxicity Patients (n) Parameter
Lung
toxicity
Cough MLD  SD (Gy)
G0 11 (18.3) 12.0  4.1
G1 34 (56.7) 13.8  4.)
G2 14 (23.3) 13.5  3.3
G3 1 (1.7) 6.9  0.0
Dyspnea MLD  SD (Gy)
G0 22 (36.7) 11.8  3.7
G1 27 (45.0) 13.5  3.9
G2 9 (15.0) 15.2  4.1
G3 2 (3.3) 16.5  3.4
Esophageal
toxicity
Esophagitis MED  SD (Gy) Dmax  SD (Gy)
G0 9 (15.0) 14.6  9.7 41.0  10.2
G1 14 (23.3) 23.4  9.3 44.1  9.7
G2 30 (50.0) 22.9  7.8 44.9  3.4
G3 7 (11.7) 24.0  6.8 47.0  0.9
334 I. J. Radiation Oncology d Biology d Physics Volume 77, Number 2, 2010concurrent chemoradiotherapy was 13% (95% CI, 7–25%).
No Grade 4 or 5 toxicity was observed. The esophagitis re-
solved within 4 weeks after RT in all patients. No significant
correlation was found between the toxicity grade and the ra-
diation parameters, neither for lung nor esophageal toxicity.Abbreviations: MLD = mean lung dose; SD = standard deviation;
G = grade; MED = mean esophageal dose; Dmax = maximal esoph-
ageal dose.
* Common Terminology Criteria for Adverse Events, version 3.0.DISCUSSION
This is the first prospective study evaluating SNI based on
FDG-PET scans in LD-SCLC patients.
In the absence of clinical evidence regarding the safety of
SNI, radiation oncologists are confronted with the choice
between a possible reduction in treatment-related toxicity
and the possibility of increasing the risk of locoregional fail-
ure (11). A Phase II trial by our group evaluating the safety of
CT-based SNI resulted in an unacceptably high percentage of
isolated regional failures (11%; 95% CI, 2–29%). In contrast,
in the present study, with SNI based on PET, isolated nodal
recurrences occurred in 3% of patients (95% CI, 1–11%).
This proportion is comparable to that found with SNI in
NSCLC, in which about 2% experienced an isolated nodal
recurrence with SNI on basis of FDG-PET scans (5, 6).
The remarkable difference between the value of SNI based
on CT vs. PET in LD-SCLC may be explained by the discrep-
ancy in the involved nodal stations on the PET and CT scans.
Indeed, we observed different lymph node stations involved
on PET compared with those on CT in 30% of our LD-SCLC
patients. The proportion of patients in whom more nodal sta-
tions were involved on PET than on CT was similar to the
percentage in whom fewer nodal stations were involved on
PET than on CT. These data correspond to those found in
the planning study we performed, in which a difference in in-
volved nodal stations in 24% of patients was observed. In our
prospective study concerning CT-based SNI for SCLC, all
isolated nodal failures occurred in the ipsilateral supraclavic-
ular area (12). The present study showed involvement of the
ipsilateral supraclavicular nodes on PET in 5% of patients
whose CT scan was negative for this region. This confirms
that PET scanning can result in the up-front detection of
supraclavicular lymph node metastases, thereby reducing
the risk of an isolated nodal recurrence in this area.Patients with an isolated nodal failure could theoretically
have been cured if elective nodal irradiation had been per-
formed instead of SNI. However, aside from the nodal recur-
rences, both local and distant recurrences still occurred in
most patients, emphasizing the need for better treatment strat-
egies for this disease.
The median OS in our study of 19 months (2-year OS rate,
35%) was lower than that reported in the trial by Turrisi et al.
(1), in which LD-SCLC patients were treated with concurrent
chemoradiotherapy with elective nodal irradiation (median
OS of 23 months and 2-year OS rate of 47%). A possible
explanation for this difference in survival is the relatively
long SER in our study (39 days; range, 20–176). Moreover,
the standard chemotherapy regimen in our region consisted
of carboplatin-etoposide, not cisplatin-etoposide chemother-
apy as in the trial by Turrisi et al. (1). Although one random-
ized prospective trial showed equal efficacy for both
treatment regimens in the treatment of SCLC (31), no defin-
itive conclusions could be drawn regarding the outcomes
with concurrent chemoradiotherapy for LD-SCLC. Finally,
in the trial by Turrisi et al. (1), patients with contralateral hilar
or supraclavicular involvement were excluded, whereas they
were included in our study.
Lung toxicity was generally mild and rare, with only 5% of
patients experiencing Grade 3 toxicity (cough or dyspnea
according to the Common Terminology Criteria for Adverse
Events, version 3.0). A remarkably low percentage of severe
acute esophagitis was found, with only 12% (95% CI, 6–22%)
of patients experiencing Grade 3 esophagitis. In patients who
have undergone elective nodal irradiation, or CT-based SNI,
PET-based selective nodal irradiation for SCLC d J. VAN LOON et al. 335Grade 3 esophagitis usually occurs in about 30% of patients
(1, 6). This cannot be straightforwardly explained by a reduc-
tion in radiation fields, because both our previous planning
study and the present trial showed an equal percentage of
increases and decreases in radiation fields when using PET
instead of CT. Possible hypotheses include the relatively
long SER in the present study (32), a lower than average neu-
tropenia level (33), which was not investigated in the present
study, or simply an observation due to chance. If the current
finding of lower esophageal toxicity holds true, PET-based
SNI could provide opportunities for dose escalation and,
hence, improvement of locoregional tumor control. There-
fore, more studies are warranted to investigate this finding.
The use of FDG-PET-CT is likely to be the most accurate
noninvasive staging method for the mediastinum in SCLC(15, 29, 34). However, the most reliable method to detect me-
diastinal nodal involvement remains pathologic verification.
The available studies have indicated that CT underestimates
mediastinal nodal involvement (35–37). No prospective data
exist concerning correlation of the pathologic findings with
PET findings in SCLC. Because of the low rate of isolated
nodal failures found in the present study and the morbidity
associated with invasive staging, we believe that our data
support the use of PET-based SNI for LD-SCLC.CONCLUSION
This prospective study shows that PET-based SNI in
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